Search Results - "Barnes, Chris N."

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease by Pudi, Krishna K, Barnes, Chris N, Moran, Edmund J, Haumann, Brett, Kerwin, Edward

“…Revefenacin is a once-daily long-acting muscarinic antagonist (LAMA) in clinical development for the treatment of patients with chronic obstructive pulmonary…”
Get full text

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) by Donohue, James F, Kerwin, Edward, Sethi, Sanjay, Haumann, Brett, Pendyala, Srikanth, Dean, Lorna, Barnes, Chris N, Moran, Edmund J, Crater, Glenn

“…Revefenacin is a long-acting muscarinic antagonist that was recently approved for the nebulized treatment of chronic obstructive pulmonary disease (COPD)…”
Get full text

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis by Donohue, James F, Kerwin, Edward, Barnes, Chris N, Moran, Edmund J, Haumann, Brett, Crater, Glenn D

“…Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 s (FEV ) in…”
Get full text

Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study by Lancaster, Lisa, Cottin, Vincent, Ramaswamy, Murali, Wuyts, Wim A., Jenkins, R. Gisli, Scholand, Mary Beth, Kreuter, Michael, Valenzuela, Claudia, Ryerson, Christopher J., Goldin, Jonathan, Kim, Grace Hyun J., Jurek, Marzena, Decaris, Martin, Clark, Annie, Turner, Scott M., Barnes, Chris N., Achneck, Hardean E., Cosgrove, Gregory P., Lefebvre, Éric A., Flaherty, Kevin R.

“…What is this summary about? This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the American Journal of…”
Get full text

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials by Sethi, Sanjay, Donohue, James F., Ferguson, Gary T., Barnes, Chris N., Crater, Glenn D.

“…Background: Combinations of a long-acting muscarinic receptor antagonist (LAMA), long-acting β-agonist (LABA), and inhaled corticosteroid (ICS) are used for…”
Get full text

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™) by Bressler, Adam M., Hassoun, Ali A., Saravolatz, Louis D., Ravenna, Valerie, Barnes, Chris N., Castaneda-Ruiz, Bibiana

“…Background Telavancin—a lipoglycopeptide antibacterial agent active against Gram-positive pathogens including methicillin-sensitive and -resistant…”
Get full text

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials by Niederman, Michael S., Lee, Patrick C., Barriere, Steven L., Barnes, Chris N., Castaneda-Ruiz, Bibiana

“…Introduction The efficacy and safety of telavancin versus vancomycin in microbiologically evaluable patients with hospital-acquired or ventilator-associated…”
Get full text

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease by Donohue, James, Kerwin, Edward, Sethi, Sanjay, Haumann, Brett, Pendyala, Srikanth, Dean, Lorna, Barnes, Chris N., Moran, Edmund J., Crater, Glenn

“…This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very…”
Get full text

Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study by Kuo, Braden, Barnes, Chris N., Nguyen, Deanna D., Shaywitz, David, Grimaldi, Maria, Renzulli, Cecilia, Canafax, Daniel, Parkman, Henry P.

“…Summary Background Gastroparesis is a serious gastrointestinal (GI) condition characterised by delayed gastric emptying (GE). Velusetrag—a potent, selective,…”
Get full text

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies by Sarafoglou, Kyriakie, Barnes, Chris N, Huang, Michael, Imel, Erik A, Madu, Ivy-Joan, Merke, Deborah P, Moriarty, David, Nakhle, Samer, Newfield, Ron S, Vogiatzi, Maria G, Auchus, Richard J

“…Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treated with lifelong supraphysiologic doses of glucocorticoids (GCs)…”
Get full text

Blinded, Double‐Dummy, Parallel‐Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5‐Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding Intolerance by Chapman, Marianne J., Jones, Karen L., Almansa, Cristina, Barnes, Chris N., Nguyen, Deanna, Deane, Adam M.

“…Background Delayed gastric emptying is the leading cause of enteral feeding intolerance (EFI) in critical illness. This phase 2a study compared TAK‐954, a…”
Get full text

Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different Inhalers by Barnes, Chris N, Mahler, Donald A, Ohar, Jill A, Lombardi, David A, Crater, Glenn D

“…Peak inspiratory flow (PIF) has been proposed as a measure to assess a patient's ability to use dry powder inhalers (DPIs). However, robust quality criteria to…”
Get full text

Editorial: on the road towards treatment of gastroparesis—accelerating, but do we get closer? Authors' reply by Kuo, Braden, Barnes, Chris N., Nguyen, Deanna D., Shaywitz, David, Grimaldi, Maria, Renzulli, Cecilia, Canafax, Daniel, Parkman, Henry P.

“…LINKED CONTENT This article is linked to Kuo et al and Wuestenberghs & Gourcerol papers. To view these articles, visit https://doi.org/10.1111/apt.16344 and…”
Get full text

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease by Donohue, James F., Kerwin, Edward, Sethi, Sanjay, Haumann, Brett, Pendyala, Srikanth, Dean, Lorna, Barnes, Chris N., Moran, Edmund J., Crater, Glenn

“…Prior replicate 12-week phase 3 trials demonstrated that once-daily doses of revefenacin inhalation solution at 88 μg and 175 μg produced significant…”
Get full text

A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis by Abell, Thomas L., Kuo, Braden, Esfandyari, Tuba, Pfeifer, Nathan D., Grimaldi, Maria, Renzulli, Cecilia, Tacchi, Raffaella, Zhou, Kefei, Barnes, Chris N., Nguyen, Deanna D., Nguyen, Linda, Talley, Nicholas J., McCallum, Richard

“…Background This study assessed the efficacy and safety of velusetrag—a 5‐HT4 agonist with pan‐gastrointestinal prokinetic activity—for gastroparesis symptom…”
Get full text

Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite by Bourdet, David L, Yeola, Suresh, Hegde, Sharath S, Colson, Pierre-Jean, Barnes, Chris N, Borin, Marie T

“…Revefenacin inhalation solution is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. Mass…”
Get full text

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial by Lancaster, Lisa, Cottin, Vincent, Ramaswamy, Murali, Wuyts, Wim A, Jenkins, R Gisli, Scholand, Mary Beth, Kreuter, Michael, Valenzuela, Claudia, Ryerson, Christopher J, Goldin, Jonathan, Kim, Grace Hyun J, Jurek, Marzena, Decaris, Martin, Clark, Annie, Turner, Scott, Barnes, Chris N, Achneck, Hardean E, Cosgrove, Gregory P, Lefebvre, Éric A, Flaherty, Kevin R

“…Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death…”
Get full text

Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials by Donohue, James F, Feldman, Gregory, Sethi, Sanjay, Barnes, Chris N, Pendyala, Srikanth, Bourdet, David, Crater, Glenn

“…The cardiovascular safety of revefenacin, an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive lung disease (COPD),…”
Get full text

Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate by Mahler, Donald A, Ohar, Jill A, Barnes, Chris N, Moran, Edmund J, Pendyala, Srikanth, Crater, Glenn D

“…Patients with chronic obstructive pulmonary disease (COPD) and suboptimal peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers…”
Get full text

714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors by Daud, Adil, Barnes, Chris N, Owen, Susan, Turner, Scott M, Sznol, Mario, Lefebvre, Eric A, Achneck, Hardean E

“…BackgroundAnalyses of transforming growth factor-β (TGF-β) expression in tumors treated with immune checkpoint inhibitors (ICIs) suggest that in the tumor…”
Get full text